Tissue-type plasminogen-activator

S. E. Builder, R. van Reis, N. Paoni, and J. Ogez, "Process Development and Regulatory Approval of Tissue-Type Plasminogen Activator," in... [Pg.57]

Fibrinolytics. Figure 3 Plasminogen activation (a) Kinetics of plasminogen activation by uPA (urokinase-type) and tPA (tissue-type) plasminogen activators. Effect of fibrin (b) Ternary complex formation between enzyme (tPA), substrate (Pg) and cofactor (F) Abbreviations plasmin (P), fibrin (F), plasminogen (Pg). Plasmin, formed in time, is expressed in arbitrary units. [Pg.505]

Tissue-type plasminogen activator (tPA) is a glycoprotein (68 kDa), synthesized by endothelial and tumor-cells. As a serine protease, tPA hydrolyses Arg561-Val562 peptide bond in plasminogen, resulting in plasmin formation. It needs cofactors for efficient plasminogen activation. [Pg.1202]

Tissue-specific Agonists/Antagonists Tissue-type Plasminogen Activator T-kinin (Ile-Ser-Bradykinin)... [Pg.1504]

Recently, a superior therapy has been approved for use by the federal government tissue-type plasminogen activator (tPA). This naturally occurring enzyme dissolves blood clots as part of the normal healing process. By administering relatively large quantities of it, clot breakdown time can be shortened from about a week to under an hour. [Pg.34]

Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 282 2019-2026 [see comment]. [Pg.35]

Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 1987 67 394-398. [Pg.56]

Katzan IL, Furlan AJ, Lloyd LE, Erank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA. Use of tissue-type plasminogen activator for acute ischemic stroke The Cleveland area experience. JAMA. 2000 283 1151-1158. [Pg.58]

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke The Standard Treatment with Alteplase to Reverse stroke (STARS) study. JAMA. 2000 283 1145-1150. [Pg.58]

Katzan IL, Hammer MD, Eurlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke A Cleveland update. Stroke. 2003 34 799-800. [Pg.58]

Grotta JC, Burgin WS, El-MitwaUi A, Long M, Campbell M, Morgenstem LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke Houston experience 1996 to 2000. Arch Neurol. 2001 58 2009-2013. [Pg.59]

An anti-intracellular adhesion molecule-1 (anti-ICAM-1) antibody reduced neurological damage in a rabbit embolic model of stroke followed by thrombolysis with tissue-type plasminogen activator (tPA). When thrombolysis was delayed for 3 h following embolism, neither tPA nor the tPA/ICAM combination reduced neurological damage. [Pg.273]

C. Hsu, H. Nguyen, D. Yeung, D. Brookes, G. Koe, T. Bewley, and R. Pearlman, Surface denaturation of solid-void interface—a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures, Pharm. Res., 12, 69 (1995). [Pg.720]

M. Mumenthaler, C. C. Hsu, and R. Pearlman, Feasibility study on spray-drying protein pharmaceuticals recombinant human growth hormone and tissue-type plasminogen activator, Pharm. Res, 11(1), 12 (1994). [Pg.721]

Lottenberg R., Sjak-Shie N., Fazleabas A. T Roberts R. M. Aprotinin inhibits urokinase but not tissue-type plasminogen activator. Thromb Res 1988 49,549-56. [Pg.168]

Mohler M. A., Refino C. J., Chen S. A., Chen A. B Hotchkiss A. J. D-Phe-Pro-Arg-chloromethylketone Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue type plasminogen activator thrombolytic therapy. Thromb Haemost 1986 56, 160-4. [Pg.168]

Kluft C., Verheijen J. H. Leiden Fibrinolysis Working Party. Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990 4(Suppl2) 155-61. [Pg.168]

M. Otter, M. M. Barett-Bergshoeff, and D. C. J. Rijken, Binding of tissue-type plasminogen activator by the mannose receptor, J. Biol. Chem., 266 (1991) 13931-13935. [Pg.386]

Tissue paper products, 13 129-130 Tissue plasminogen activator (t-PA) bioseparation from mammalian cell culture, 3 821-826 peptide map, 3 841, 842 selling price, 3 817t Tissue reactions, to sutures, 24 218 Tissue-type plasminogen activator (t-PA) and hemostatic system, 4 89 human, use as thrombolytic agent,... [Pg.952]

The heterogeneity of Lp(a) is related to ultrastructural motifs in the molecule, strongly resembling the so-called kringles found in both plasminogen and other plasma proteins, such as proteases of the coagulation system (tissue type plasminogen activator and prothrombin) (Fig. 2). [Pg.75]

As apo(a) differs from plasminogen on sites 560 (Ser instead of Arg) and 561 (lie instead of Val) in the protease part, it cannot be activated in the same way as plasminogen, as on these sites tissue type plasminogen activator (tPA) acts as activator. There is no plasmin-like activity of Lp(a) alter incubation with tPA. [Pg.97]

Interaction ofLp(a) in the Process of Activation of Plasminogen to Plasmin by Tissue-Type Plasminogen Activator on Fibrin, Fibrinogen, and Fibrin(ogen) Fragments... [Pg.97]

A17. Aznar, J., Estelles, A., Breto, M., Espana, F., and Aids, T., Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipopro-tein(a). Thromb. Res. 66, 569-582 (1992). [Pg.112]

RI7. Rouy, D., Grailhe, P., Nigon, F., Chapman, J., and Angles-Cano, E., Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arterioscler. Thromb. 11, 629-638 (1991). [Pg.128]

Andersen D.C., Bridges T., Gawlitzek M., and Hoy C. (2000), Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator, Biotech. Bioeng. 70, 25-31. [Pg.272]

Benchenane K, Lopez-Atalaya J-P, Fernandez-Monreal M, et al. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 2004 27 155-60. [Pg.79]

Sobel BE, Geltman EM, Tiefenbrunn AJ, Jaffe AS, Spadaro JJ, Jr., Ter-Pogossian MM et al. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 1984 69 983-990... [Pg.34]

Currently, in both arterial and venous occlusion, newer products such as alteplase which is recombinant human tissue-type plasminogen activator where 10 mg is given as an intitial bolus and a further 90 mg infused over 2 hours are offering alternative regimens. Although costly they have apparent benefit in stroke and acute coronary syndromes. [Pg.748]

See also in sourсe #XX -- [ Pg.67 ]

See also in sourсe #XX -- [ Pg.163 ]

See also in sourсe #XX -- [ Pg.163 ]

See also in sourсe #XX -- [ Pg.621 ]

See also in sourсe #XX -- [ Pg.621 ]

See also in sourсe #XX -- [ Pg.112 , Pg.221 , Pg.222 , Pg.225 , Pg.226 , Pg.229 , Pg.230 , Pg.231 , Pg.232 , Pg.233 , Pg.234 , Pg.235 , Pg.241 , Pg.281 , Pg.283 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...